Recently, P-Cure Medical Group has completed the global production and development base of the ultra-small proton therapy system. The international cutting-edge large-scale medical device project is located in Weifang City, Shandong Province. After the base is put into operation, it will have the capacity of producing 10 units (sets) of proton therapy system annually at the initial stage. At that time, Weifang will become an important supply base for PCure global proton therapy system.

The project is jointly built by The Sino-Israeli Health Alliance and Weifang Economic Development Zone, and the Sino-Israeli Health Alliance is jointly established by P-Cure and Weifang City Investment. The overall planning area of the project is about 41,710 square meters, and the building area of the factory is 19,600 square meters. There are 5 shielded accelerator debugging rooms and 4 shielded treatment rooms for debugging.

The P-Cure ultra-compact proton therapy system is compact and takes up less than 200 square meters, allowing for rapid delivery and low operational cost in an existing machine room.

Accelerator: The small synchrotron is only 5 meters in diameter and about 1 meter in height. It can be installed in an existing radiotherapy department of the hospital to reduce construction cost.

Treatment technology: Using the technology of rotating chair in sit-stand position and vertical CT. The sit-stand position can make the movement of internal organs smaller while making breathing and saliva excretion more smoothly. The patient can utilize simulated CT in an upright position and can be treated without position changing.

Treatment room: Rotating seat + vertical CT reduces the volume of the treatment room, and the treatment equipment takes less than 200 square meters.

Auxiliary equipment: The system is equipped with two sets of X-ray sources and a retractable detector plate FPD for pre-treatment auxiliary positioning.

The P-Cure Group is currently applying to the US FDA for its ultra-small proton therapy system and is expected to receive the FDA approval in early 2022. The P-Cure group's global research and development base is in Israel, where clinical trials are underway for the treatment of the head, neck, chest and upper abdomen.